{"analyses":[{"ciLowerLimit":"-7.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.0","estimateComment":"Treatment difference= Relugolix - Leuprolide acetate","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Treatment difference","paramValue":"-2.9"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.3","upperLimit":"87.3","value":"84.6"},{"groupId":"OG001","lowerLimit":"83.0","upperLimit":"90.8","value":"87.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Sustained profound castration rate was defined as the cumulative probability of testosterone suppression to \\< 20 ng/dL. The rate was estimated by the Kaplan-Meier method and reported as percentage of participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug and had analyzable data at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Week 25 Day 1 (Day 169) through Week 49 Day 1 (Day 337)","title":"Sustained Profound Castration Rate From Week 25 Day 1 Through Week 49 Day 1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}